about
Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaToll-like receptors on B-CLL cells: expression and functional consequences of their stimulation.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentThe role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies.Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.Evaluation of sericin as a fetal bovine serum-replacing cryoprotectant during freezing of human mesenchymal stromal cells and human osteoblast-like cells.High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.New aspects of galectin functionality in nuclei of cultured bone marrow stromal and epidermal cells: biotinylated galectins as tool to detect specific binding sites.Detection of cell type and marker specificity of nuclear binding sites for anionic carbohydrate ligands.Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.Expression of genes regulating angiogenesis in human circulating hematopoietic cord blood CD34+/CD133+ cells.The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trialIntracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized studyThe WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working GroupCirculating endothelial progenitor cells in patients with ANCA-associated vasculitisCharacterization of dental pulp stem cells from impacted third molars cultured in low serum-containing mediumAnalysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemiaRituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disordersPre-transplant positron emission tomography in patients with relapsed Hodgkin lymphomaDistinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reactionThe evaluation of survival and proliferation of lymphocytes in autologous mixed leukocyte reaction with dendritic cells. The comparison of incorporation of (3)H-thymidine and differential gating methodReply to the letter to the editor by Guinn et alCan Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry
P50
Q30649483-48ADEC96-92FD-4556-92C6-298719628731Q33494116-81BE2EAD-8A4A-4BE3-8751-D35312D20CCBQ33945770-7050BC1D-C2E2-41FF-8E20-28A4251EB6A2Q37705531-5F90E2F9-F5C2-46D7-8F81-D74D4852A065Q38827910-D719705D-3B3D-4330-981F-8E3EB19E491DQ38893324-A2797347-362D-4276-ADE1-FD58ED643C10Q40625080-053982F3-8732-49B1-B956-BAFC2F31776EQ41465999-E845AA29-12E2-4413-81EA-6A1EF669DCFAQ42453087-22A66EFE-7564-44A4-B383-41FE80A8EB80Q42819894-A5198156-B484-4193-BC46-85F0CD002052Q43930995-9482D96A-E8DD-4E4C-8597-1AB7AD101C69Q44328125-D2ABD26C-9D38-4D18-93C5-78AF7284C970Q45332589-22B2EBD7-405D-4D7D-AA9F-6A44E3EB217CQ45964181-7151C0F1-6EC3-494A-974C-385EEF6E735AQ46334893-A759088E-DAC6-4583-940C-3863D9BCA642Q48105468-213B8E80-A2E3-4499-9875-C2C8D82D79D9Q48274743-AFF1B013-14B7-45C5-8A95-4D933C1CD7B4Q79248931-64EF1794-9BDB-47E7-B6E7-691CBB2CF42CQ80485648-27E05272-C1E2-4E66-874D-AD70ADDE9B08Q81100912-4A79EF9C-D84F-4F76-BF7A-20B970BC2E3EQ81577334-D39A6198-1669-496D-A68D-10D37A35F62EQ82432912-F5F3CC87-9A7E-457A-9BB3-08EB058AF523Q83284231-E82A5BA3-1803-4115-BC32-021E4258C42DQ84299396-09D12EFF-8ED9-4BE9-827B-BAF428025EF5Q84431044-1AD78B70-DDA4-44FB-A35D-978197AFF88AQ84456774-ECDEC314-28FD-431E-B77A-305453C610ECQ84622310-53A39DC1-A7E8-4937-B516-4455A907CD36Q84869316-52931991-620D-494F-978F-4A09175DB3BFQ85233591-67D8512A-F02F-45B0-8FE1-F362D0E4E8B0Q89228728-66BD3971-BCF9-41F2-B470-F68637F646C1
P50
description
hematolog
@cs
researcher ORCID ID = 0000-0002-0517-2691
@en
wetenschapper
@nl
name
Robert Pytlik
@ast
Robert Pytlik
@es
Robert Pytlik
@nl
Robert Pytlík
@cs
Robert Pytlík
@en
type
label
Robert Pytlik
@ast
Robert Pytlik
@es
Robert Pytlik
@nl
Robert Pytlík
@cs
Robert Pytlík
@en
prefLabel
Robert Pytlik
@ast
Robert Pytlik
@es
Robert Pytlik
@nl
Robert Pytlík
@cs
Robert Pytlík
@en
P214
P1153
6602559506
P214
P31
P496
0000-0002-0517-2691
P569
1967-01-01T00:00:00Z
P691
P735
P7859
viaf-85696490